Literature DB >> 12009758

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Eric K Richfield1, Mona J Thiruchelvam, Deborah A Cory-Slechta, Charles Wuertzer, Raul R Gainetdinov, Marc G Caron, Donato A Di Monte, Howard J Federoff.   

Abstract

Human alpha-synuclein (halpha-SYN) is implicated in the Parkinson's disease phenotype (PDP) based on a variety of studies in man, animal models, and in vitro studies. The normal function of halpha-SYN and the mechanism by which it contributes to the PDP remains unclear. We created transgenic mice expressing either wild-type (hwalpha-SYN) or a doubly mutated (hm2alpha-SYN) form of halpha-SYN under control of the 9-kb rat tyrosine hydroxylase promoter. These mice expressed halpha-SYN in cell bodies, axons, and terminals of the nigrostriatal system. The expression of halpha-SYN in nigrostriatal terminals produced effects in both constructs resulting in increased density of the dopamine transporter and enhanced toxicity to the neurotoxin MPTP. Expression of hm2alpha-SYN reduced locomotor responses to repeated doses of amphetamine and blocked the development of sensitization. Adult hwalpha-SYN-5 transgenic mice had unremarkable dopaminergic axons and terminals, normal age-related measures on two motor coordination screens, and normal age-related measures of dopamine (DA) and its metabolites. Adult hm2alpha-SYN-39 transgenic mice had abnormal axons and terminals, age-related impairments in motor coordination, and age-related reductions in DA and its metabolites. Expression of hm2alpha-SYN adversely affects the integrity of dopaminergic terminals and leads to age-related declines in motor coordination and dopaminergic markers. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009758     DOI: 10.1006/exnr.2002.7882

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  86 in total

1.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 2.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 3.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 4.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

Review 5.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

6.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

Authors:  Lee J Martin; Yan Pan; Ann C Price; Wanda Sterling; Neal G Copeland; Nancy A Jenkins; Donald L Price; Michael K Lee
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

7.  Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

Authors:  Wai Haung Yu; Yasuji Matsuoka; István Sziráki; Audrey Hashim; John Lafrancois; Henry Sershen; Karen E Duff
Journal:  Neurochem Res       Date:  2007-11-13       Impact factor: 3.996

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.